Via Nova Therapeutics Announces $20 Million Series A Financing From Aditum Bio To Advance Four Antiviral Programs
Via Nova Therapeutics Announces $20 Million Series A Financing From Aditum Bio To Advance Four Antiviral Programs
09/07/21, 1:00 PM
Location
Money raised
$20 million
Round Type
series a
Via Nova Therapeutics announced today that it has closed its Series A financing and raised $20 million from Aditum Bio to advance the development of four preclinical antiviral programs in-licensed from Novartis. The firm, founded by virologists Don Ganem, MD and Kelly Wong, PhD, was established to discover and develop therapeutics for acute and subacute viral infections for which current treatments are lacking or inadequate. The current programs at Via Nova were part of an antiviral portfolio led by the founders while at Novartis and target several important respiratory viruses (including influenza viruses, adenoviruses and rhinoviruses) as well as human polyomaviruses, which produce severe disease in immunocompromised hosts. The firm targets fundamental mechanisms of viral replication and accordingly can support discovery of novel therapeutics for other viral infections as well.
Company Info
Company
Via Nova Therapeutics
Location
oakland, california, united states
Additional Info
The firm targets fundamental mechanisms of viral replication and accordingly can support discovery of novel therapeutics for other viral infections as well.